Researchers from the Radiopharmaceutical Sciences Group of C2TN integrate a new Coordinated Research Project (CRP) from the IAEA, which had its first meeting in December in Vienna, Austria. This CRP aims to develop and carry out preclinical evaluation of Lu-177 radiopharmaceuticals targeting some of the major types of cancer. The consortium involves 16 Participating Countries from Europe, North and South America and Asia, and the team from Portugal is led by Filipa Mendes, Principal Investigator at C2TN.
C2TN participates in a new Research Project from the IAEA
